Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All N‑acetylcysteine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchN-acetylcysteineN-acetylcys.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -19% Improvement Relative Risk ICU admission -34% Discharge 1% N-acetylcysteine for COVID-19  STORM  LATE TREATMENT Is late treatment with N-acetylcysteine beneficial for COVID-19? Retrospective 901 patients in Italy (February 2020 - April 2021) Higher mortality (p=0.33) and ICU admission (p=0.08), not sig. c19early.org Faverio et al., ERJ Open Research, Dec 2021 Favors N-acetylcysteine Favors control

Impact of N-acetyl-l-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study

Faverio et al., ERJ Open Research, doi:10.1183/23120541.00542-2021, STORM, NCT04424992
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
13th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000034 from 24 studies, recognized in 3 countries.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 1,083 consecutive hospitalized COVID patients in Italy, showing no significant differences with NAC treatment. The number of patients transferred to another facility exceeds the number of deaths, which may significantly affect results.
risk of death, 19.0% higher, RR 1.19, p = 0.33, treatment 91 of 572 (15.9%), control 44 of 329 (13.4%), propensity score weighting.
risk of ICU admission, 33.8% higher, RR 1.34, p = 0.08, treatment 107 of 572 (18.7%), control 46 of 329 (14.0%), propensity score weighting.
risk of no hospital discharge, 1.4% lower, RR 0.99, p = 0.94, treatment 180 of 572 (31.5%), control 105 of 329 (31.9%), NNT 224, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Faverio et al., 2 Dec 2021, retrospective, Italy, peer-reviewed, 10 authors, study period February 2020 - April 2021, trial NCT04424992 (history) (STORM).
This PaperN-acetylcys..All
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study
Paola Faverio, Paola Rebora, Emanuela Rossi, Savino Del Giudice, Filippo Montanelli, Laura Garzillo, Sara Busnelli, Fabrizio Luppi, Maria Grazia Valsecchi, Alberto Pesci
doi:10.1183/23120541.00542-2021].
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may cause pneumonia and acute respiratory distress syndrome (ARDS), whose pathogenesis has been partially related to an increased systemic inflammatory response with great production of pro-inflammatory cytokines causing a "cytokine storm" and an oxidative stress imbalance [1]. N-acetyl-L-cysteine (NAC) is a precursor of reduced glutathione [2] that has antioxidant, anti-inflammatory and immunomodulating properties that may prove beneficial in modulating the excessive inflammatory activation during coronavirus disease (COVID-19) [3]. Furthermore, NAC has been extensively used as a mucolytic agent to improve airway clearance in chronic respiratory diseases. During the COVID-19 pandemic research hypotheses on the role of NAC have been formulated and randomised control trials (RCT) are ongoing; however, to date only a few case reports have been published [3, 4]. The aim of our study is to evaluate the impact of NAC administered during hospitalisation for SARS-CoV-2 pneumonia on short-term and long-term outcomes. As short-term outcomes we considered in-hospital mortality, intensive care unit (ICU) admission, length of ICU stay and length of hospital stay (LOS) in patients discharged alive; as long-term outcomes we included diffusion capacity of the lung for carbon monoxide (D LCO ) impairment, chest radiography alterations, reduced distance walked in the 6-min walk test (6MWT) and dyspnoea score (modified Medical Research Council (mMRC) scale) at 6 months follow-up in a subset of patients included in a follow-up study. Furthermore, we will also evaluate the impact of NAC on the development of atelectasis during hospitalisation, a possible complication of SARS-CoV-2 pneumonia. We performed a retrospective monocentric study on 1083 consecutive adult patients hospitalised for SARS-CoV-2 pneumonia at the San Gerardo Hospital, Monza, Italy, between February 2020 and April 2021. Given that the aim was to evaluate the impact of a least 5 days of NAC administration, patients were excluded if they died or were discharged within 5 days from admission (n=177) to avoid immortal time bias. NAC was introduced, as per institutional protocol, on admission and administered at a dosage of 300 mg intravenously three times daily, switched to 600 mg per os twice daily once the patient reached clinical stability and continued until discharge. The study (STORM) was approved by the national Institutional Review Board (Spallanzani Hospital), and registered at ClinicalTrials.gov with identifier NCT04424992. As part of a multi-centre prospective study to evaluate pulmonary sequelae caused by SARS-CoV-2 pneumonia [5] (ClinicalTrials.gov identifier: NCT04435327), we also had available follow-up data on 102 patients from the original cohort alive at discharge. The follow-up consisted of a pneumological visit at 6 months including complete pulmonary function tests and D LCO , 6MWT, mMRC scale and..
Author contributions: A. Pesci and M.G. Valsecchi are the guarantors of this research. P. Faverio, P. Rebora, E. Rossi, S. Busnelli and A. Pesci were responsible for study concept and design. P. Faverio, S. del Giudice, F. Montanelli, L. Garzillo, S. Busnelli and F. Luppi contributed to patient recruitment and follow-up. All authors contributed to data acquisition. P. Faverio, P. Rebora, E. Rossi, S. Busnelli and M.G. Valsecchi performed data analysis. P. Faverio, P. Rebora, S. Busnelli and F. Luppi contributed to the drafting of this manuscript. All authors read and approved the final manuscript.
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit